Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 25, 2019
Tools & Techniques
NASH: how non-invasive biomarkers promise to displace biopsies
Long-term, biomarkers will replace biopsies in NASH. Short-term, they’re aiding patient recruitment.
BioCentury | Nov 19, 2016
Strategy
Adding on in fibrosis
Why Bristol-Myers licensed Nitto Denko’s antifibrotic Hsp47 therapy
BioCentury | May 25, 2015
Company News
Ambrx, China Everbright, Hopu Investment Management, Shanghai Fosun Pharmaceutical, WuXi PharmaTech deal
BioCentury | Jul 14, 2014
Finance
3Q14 Financial Markets Preview: Discerning optimism
Biotech investors: bottom hit but will be selective on IPOs, small caps in 3Q14
Items per page:
1 - 10 of 16